Skip to main content

Juluca Side Effects

Generic name: dolutegravir / rilpivirine

Medically reviewed by Drugs.com. Last updated on May 22, 2024.

Note: This document provides detailed information about Juluca.

Applies to dolutegravir / rilpivirine: oral tablet Side Effects associated with dolutegravir / rilpivirine. Some dosage forms listed on this page may not apply specifically to the brand name Juluca.

Applies to dolutegravir / rilpivirine: oral tablet.

Precautions

It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.

It is important to tell your doctor if you are pregnant or planning to become pregnant before using this medicine. Using this medicine while you are pregnant can harm your unborn baby. If you are a woman who can get pregnant, your doctor may do tests to make sure you are not pregnant before starting treatment. Do not use this medicine during the first part of your pregnancy unless your doctor tells you to. Use an effective form of birth control to keep from getting pregnant.

This medicine should not be used together with dexamethasone (Decadron®), dofetilide (Tikosyn®), certain seizure medicines (eg, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, Dilantin®, Tegretol®, Trileptal®), medicine for tuberculosis (eg, rifampin, rifapentine, Priftin®, Rifadin®, Rimactane®), certain stomach medicines (eg, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, Aciphex®, Nexium®, Prevacid®, Prilosec®) or St. John's wort.

This medicine may cause serious allergic reactions including anaphylaxis and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening and requires immediate medical attention. Call your doctor right away if you or your child have black, tarry stools, chest pain, chills, cough, fever, painful or difficult urination, rash, itching, hoarseness, lightheadedness or dizziness, sore throat, sores, ulcers, or white spots on the lips or in the mouth, swollen glands, trouble breathing, trouble swallowing, unusual bleeding or bruising, unusual tiredness or weakness, or any swelling of your hands, face, or mouth with this medicine.

This medicine may cause serious liver problems. This may occur in patients with hepatitis B or C infection. Check with your doctor right away if you or your child have clay-colored stools, dark urine, a decreased appetite, fever, headache, itching, nausea and vomiting, skin rash, stomach pain or tenderness, swelling of the feet or lower legs, unusual tiredness or weakness, or yellow eyes or skin.

Tell your doctor right away if you start to feel depressed and have thoughts about hurting yourself. Report any unusual thoughts or behavior that troubles you, especially if they are new or get worse quickly.

This medicine will not keep you from giving HIV to your partner during sex. Make sure you understand this and practice safe sex, even if your partner also has HIV, by using a latex condom or other barrier method. This medicine will also not keep you from giving HIV to other people if they are exposed to your blood. Do not re-use or share needles with anyone.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Juluca

Along with its needed effects, dolutegravir / rilpivirine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dolutegravir / rilpivirine:

Less common side effects

  • abnormal dreams
  • anxiety
  • cloudy or bloody urine
  • dark urine
  • decreased frequency or amount of urine
  • depressed mood
  • gaseous stomach pain
  • increased blood pressure
  • increased thirst
  • indigestion
  • light-colored stools
  • loss of appetite
  • lower back or side pain
  • nausea
  • recurrent fever
  • severe nausea or vomiting
  • stomach fullness or pain
  • swelling of the face, fingers, feet, or lower legs
  • thoughts or attempts at killing oneself
  • trouble sleeping
  • trouble breathing
  • unusual tiredness or weakness
  • upper right abdominal or stomach pain
  • vomiting
  • weight gain
  • yellow eyes or skin

Incidence not known

  • black, tarry stools
  • chest pain
  • chills
  • cough
  • decreased appetite
  • difficulty swallowing
  • fast heartbeat
  • fever
  • headache
  • painful or difficult urination
  • skin itching, rash, or redness
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • stomach tenderness
  • stomach pain, continuing
  • swelling of the face, throat, or tongue
  • swollen glands
  • unusual bleeding or bruising

Other side effects of Juluca

Some side effects of dolutegravir / rilpivirine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common side effects

  • bloated feeling
  • diarrhea
  • dizziness
  • excess air or gas in the stomach or bowels
  • feeling of fullness
  • muscle pain
  • passing gas
  • sleepiness or unusual drowsiness

Incidence not known

  • difficulty in moving
  • joint pain or swelling
  • muscle ache, cramp, or stiffness

For healthcare professionals

Applies to dolutegravir / rilpivirine: oral tablet.

General adverse events

In clinical trials, dolutegravir plus rilpivirine was discontinued due to side effects in 4% of patients. The most common side effects leading to discontinuation were psychiatric disorders.[Ref]

Nervous system

Dolutegravir:

Rilpivirine:

Gastrointestinal

Dolutegravir:

Rilpivirine:

Grade 2 and grade 3 to 4 elevations in lipase were reported in 5% and 2% of patients, respectively.[Ref]

Other

Dolutegravir:

Rilpivirine:

Psychiatric

Dolutegravir:

Rilpivirine:

Suicidal ideation or suicide attempt was reported, mainly in patients with history of depression or psychiatric illness.

Depressive disorders occurred primarily in patients with history of depression or other psychiatric illness.[Ref]

Hepatic

Dolutegravir:

Rilpivirine:

Grade 2 and grade 3 to 4 elevations in ALT were reported in 2% and less than 1% of patients, respectively. Grade 2 elevations in total bilirubin were reported in 2% of patients. Grade 2 and grade 3 to 4 elevations in AST were each reported in less than 1% of patients.

The incidence of liver chemistry elevations was higher in patients coinfected with hepatitis C than in those who were not coinfected.

In some patients using dolutegravir-containing regimens, elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, especially when antihepatitis therapy was stopped.[Ref]

Metabolic

Rilpivirine:

Grade 2 and grade 3 to 4 hyperglycemia were reported in 4% and less than 1% of patients, respectively.[Ref]

Musculoskeletal

Dolutegravir:

BMD increased (total hip and lumbar spine) from baseline to week 48 in patients who switched from a tenofovir disoproxil fumarate (DF)-containing antiretroviral regimen to dolutegravir plus rilpivirine compared with patients who continued using a tenofovir DF-containing antiretroviral regimen. BMD declines of at least 5% at the lumbar spine were reported in 2% of patients using this drug and 5% of patients who continued using a tenofovir DF-containing antiretroviral regimen. The long-term clinical relevance of such BMD changes has not been established.

Grade 2 and grade 3 to 4 elevations in creatine phosphokinase were reported in less than 1% and 1% of patients, respectively.

Elevated creatine phosphokinase was reported, primarily associated with exercise.[Ref]

Dermatologic

Dolutegravir:

Rilpivirine:

Grade 2 to 3 therapy-related rashes were reported in 3% of patients during phase 3 trials of rilpivirine.[Ref]

Respiratory

Hematologic

Hypersensitivity

Dolutegravir:

Renal

Rilpivirine:

Both components of this drug have increased serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 48 weeks. A mean change from baseline of 0.093 mg/dL (range: -0.3 to 0.58 mg/dL) or 8.22 mcmol/L (range: -26.5 to 51.2 mcmol/L) was reported after 48 weeks of therapy; these changes were not considered clinically significant.[Ref]

Immunologic

Dolutegravir:

Combination antiretroviral therapy:

Endocrine

Rilpivirine:

In the pooled phase 3 trials, at week 96, there was an overall mean change from baseline in basal cortisol of -0.69 mcg/dL in the rilpivirine group, and of -0.02 mcg/dL in the efavirenz group.

In the rilpivirine group, 43 of 588 patients with normal 250 mcg ACTH stimulation test at baseline developed abnormal 250 mcg ACTH stimulation test (peak cortisol level less than 18.1 mcg/dL) during the trial versus 18 of 561 patients in the efavirenz group. Abnormal 250 mcg ACTH stimulation test at week 96 was seen in 14 of the 43 rilpivirine patients and 9 of the 18 efavirenz patients. Overall, there were no serious side effects, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency. Clinical significance of abnormal 250 mcg ACTH stimulation tests in the rilpivirine group has not been established.[Ref]

See also:

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. Cerner Multum, Inc. "Australian Product Information."

3. (2017) "Product Information. Juluca (dolutegravir-rilpivirine)." ViiV Healthcare

4. (2011) "Product Information. Edurant (rilpivirine)." Tibotec Pharmaceuticals

Frequently asked questions

Further information

Juluca side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.